CHMP recommends Zybrivo
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for Zybrivo (sintilimab), given with chemotherapy, for the first-line treatment of adults with advanced non-squamous non-small cell lung cancer, Innovent said. The company said it was the first positive opinion it had received from the committee.
The ORIENT-11 trial
The opinion is supported by the Phase 3 ORIENT-11 study, which enrolled 397 adults with locally advanced, metastatic or recurrent non-squamous disease and no EGFR or ALK genomic tumour aberrations. Participants were assigned 2:1 to sintilimab or placebo, each combined with pemetrexed and platinum-based chemotherapy, and the primary endpoint was progression-free survival as assessed by a blinded independent radiological review committee.
In the study, the sintilimab arm showed a 52% reduction in the hazard of disease progression or death, with median progression-free survival of 8.9 months against 5.0 months, and a 35% reduction in the hazard of death, with median overall survival of 24.2 months against 16.8 months. The company said the safety profile matched what is known of PD-1 inhibitors and the chemotherapy agents used, and that no new safety signals were identified.
Decision and territory
Following the opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the authorization would be valid in all 27 European Union member states as well as Iceland, Norway and Liechtenstein.
Use in China
Sintilimab is approved in China for ten indications, and the company said it has been used to treat approximately 3 million patients there.